Thursday, December 19, 2024

Octagos Health Secures Over $43 Million Investment to Advance AI-Driven Cardiac Device Monitoring

Related stories

Lockheed Martin Adds IBM Granite to its Suite of Next-Generation AI Factory Tools

Lockheed Martin, a longtime leader in harnessing artificial intelligence...

Ataccama Enhances Generative AI for Data Quality

Ataccama, an AI-powered data management company, announced enhancements to...

Trane Technologies to Acquire BrainBox AI

Trane Technologies, a global climate innovator, announced that it...

Suki Unveils Patient Summarization and Clinical Q&A for Doctors With Google Cloud

Suki, the leader in AI technology for healthcare, announced...

Hamming.ai Announces $3.8 Million Seed Led by Mischief

Hamming.ai, the AI voice agent reliability platform, announced that...
spot_imgspot_img

Octagos Health, an industry-leading provider of AI-driven cardiac device monitoring solutions, announced a successful equity raise of over $43 million in investment capital. The Series B investment round was led by funds managed by Morgan Stanley Expansion Capital, with continued participation from Mucker Capital and other strategic investors. This funding will accelerate Octagos Health’s mission to use artificial intelligence to revolutionize cardiac care and provide comprehensive patient monitoring services.

Octagos Health provides an AI-driven platform that offers continuous monitoring and data analysis for patients with cardiac devices (pacemakers, defibrillators, ambulatory monitors, consumer wearables, and other modalities). Atlas AI, the company’s proprietary technology, ensures high accuracy and sensitivity in detecting clinically relevant events, automating physician workflows, and enabling healthcare providers to make informed decisions and improve patient outcomes. The platform’s comprehensive capabilities include seamless integration with electronic health records (EHR) and customizable reporting features, making it a preferred choice for cardiology practices.

“By combining AI, patient services, and bidirectional EHR integration, the Octagos Health platform enables cardiologists to efficiently monitor patients, improve patient care, and enhance clinic economics. The funding will help us accelerate our growth across the US and expand into other critical areas of cardiac care, including ambulatory monitors, consumer wearables, and sleep.  Our goal is to build a comprehensive AI-based clinical decision support engine for healthcare. We are thrilled to have Morgan Stanley Expansion Capital as our lead investor and the continued support of Mucker Capital. In a short period, we have grown from first servicing my cardiology clinic to becoming one of the largest cardiac remote monitoring companies that provides software and services,” said Dr. Shanti Bansal, cardiologist, CEO of Octagos Health and Houston Heart Rhythm.

Also Read: Element Announces RegNav, its First AI-Powered Platform Promoting Safer and More Reliable Medical Device Development

“This investment will enable us to accelerate enhancements to our platform, in addition to scaling our commercial team and operations. We are currently the only company that helps cardiology practices migrate their historical data from legacy software providers and fully integrates with any EHR system. We do this while enabling customized reporting supported by patient and practice decision-support analytics,” said Eric Olsen, COO of Octagos Health.

“We are excited to partner with Octagos Health and support their vision of transforming cardiac care,” said Melissa Daniels, Managing Director of Morgan Stanley Expansion Capital. “Octagos Health has demonstrated exceptional growth and innovation in a critical area of healthcare. We believe their platform and vertically integrated software and services significantly improve patient care and streamline cardiac monitoring processes for healthcare providers.”

Octagos Health is poised for scale – industry leading gross margins, a very sticky product that doctors and clinical staff love, and a market ready for disruption with artificial intelligence. This is the new wave for diagnostic care,” said Will Hsu, Co-Founder and Partner at Mucker Capital. “This funding will help Octagos Health continue to add additional data sources from various diagnostic and consumer devices and further differentiate their offering.”

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img